Sanofi Suffers Another Sales Dip For 'Gift to Public Health' Vaccines

Why It Matters

The decline highlights how U.S. policy and anti‑vaccine sentiment can erode a major revenue stream for global pharma, while Sanofi’s strategic acquisitions and strong non‑vaccine portfolio aim to offset the impact and sustain growth.

Key Takeaways

• 2025 vaccine revenue fell 2.5% to €2 bn.
• Flu and COVID-19 sales rose 31.5% YoY.
• Dupixent drove overall sales growth, boosting net revenue.
• Sanofi bought Dynavax for $2.2 bn during vaccine slump.
• U.S. policy changes increase vaccine skepticism, affecting revenues.

Pulse Analysis

The global vaccine market entered 2025 under a cloud of heightened skepticism, particularly in the United States where recent policy shifts by Health Secretary Robert F. Kennedy Jr. removed COVID‑19 from routine schedules and amplified doubts about measles immunizations. These moves have tightened access and dampened demand for several established products, pressuring the revenue streams of industry giants such as Sanofi, Merck, Pfizer and GSK. Analysts attribute the slowdown to a combination of regulatory uncertainty, public‑health misinformation, and a fragmented immunization landscape that is reshaping growth expectations for vaccine manufacturers.

Sanofi’s full‑year results reflect this turbulence, with vaccine sales slipping 2.5% to €2 bn, while its flu and COVID‑19 lines bucked the trend, posting a 31.5% year‑on‑year increase thanks to unexpected virus activity and higher uptake. The company’s broader portfolio offset the dip: Dupixent generated €15.7 bn, Altuviiio surged 78%, and the recent $2.2 bn acquisition of Dynavax adds a promising hepatitis B pipeline. By leveraging strong biologics and specialty drugs, Sanofi delivered a 9.9% rise in net sales to €43.63 bn, illustrating the value of diversification in a volatile vaccine environment.

Looking ahead, Sanofi projects high‑single‑digit growth for 2026, betting that evidence‑based communication and strategic investments will restore confidence in immunization. The Dynavax deal positions the group to capture emerging market opportunities and mitigate future policy shocks, while continued emphasis on data‑driven advocacy aims to counteract misinformation. Investors will watch how the firm balances vaccine recovery with its expanding specialty franchise, a dynamic that could set a benchmark for other pharma players navigating the intersection of public‑health policy and commercial performance.